Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma
Roberta Soscia(Sapienza University of Rome), Ilaria Del Giudice(Sapienza University of Rome), Donatella Talotta(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Maurizio Martelli(Sapienza University of Rome), Giovanni Manfredi Assanto(Policlinico Umberto I), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luigi Petrucci(Sapienza University of Rome), Alice Di Rocco(Policlinico Umberto I), Irene Della Starza(Associazione Italiana Ematologia Oncologia Pediatrica), Marco Antonacci(Sapienza University of Rome), Teresa Bellissimo(Sapienza University of Rome), Vittorio Bellomarino(Sapienza University of Rome), Anna Guarini(Sapienza University of Rome), Robin Foà(Sapienza University of Rome)
Cited by 7
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644